PULM · Pulmatrix, Inc. · Investor Relations
$1.40
-0.02 (-1.41%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, management believes that without the closing of the Merger, given our current cash position and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about our ability to continue as a going concern after the date that is one year from the date that these financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.19M
Shares
3.65M
Volume · Oct 23
2613
Avg daily vol (3M)
26.63K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2024-11-13 | Pulmatrix - Cullgen Webcast | Webcast |
| 2023-06-15 | Pulmatrix's poster on PUR3100 Phase 1 data presented at the 65th Annual Meeting of the American Headache Society | Shareholder meeting |
| 2023-06-05 | BIO Annual International Convention Corporate Presentation | Presentation |
| 2023-02-03 | Pulmatrix KOL Event on PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment - LifeSci Events | Event |
| 2021-04-23 | KOL Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine | Event |